Biostage Raises $4.2 Million from China Investor for Bioengineered Organs

Biostage of Massachusetts raised $4.2 million in a private placement led by China's DST Capital, a Hong Kong all-industry investor focused on China. Biostage is developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea. Because of the investment, Biostage will build a presence in China , which is home to the largest incidence of esophageal cancer worldwide. More details.... Stock Symbols: (OTCQB: BSTG/BSTGD) Share this with colleagues: // //